Article · Wikipedia archive · Last revised Aug 1, 2026

AZD3676

AZD3676 is a drug which acts as a potent and selective antagonist for the 5-HT1A receptor and 5-HT1B receptors, with some selectivity for 5-HT1A. It has been researched for potential applications in the treatment of cognitive impairment in Alzheimer's disease.

Last revised
Aug 1, 2026
Read time
≈ 1 min
Length
163 w
Citations
2
Source
Wikipedia ↗
AZD3676
Clinical data
Other namesAZD-3676
Drug classSerotonin 5-HT1A and 5-HT1B antagonist
ATC code
  • None
Identifiers
  • N,N-dimethyl-7-[4-(2-pyridin-2-ylethyl)piperazin-1-yl]-1-benzofuran-2-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC22H26N4O2
Molar mass378.476 g·mol−1
3D model (JSmol)
  • CN(C)C(=O)C1=CC2=C(O1)C(=CC=C2)N3CCN(CC3)CCC4=CC=CC=N4
  • InChI=1S/C22H26N4O2/c1-24(2)22(27)20-16-17-6-5-8-19(21(17)28-20)26-14-12-25(13-15-26)11-9-18-7-3-4-10-23-18/h3-8,10,16H,9,11-15H2,1-2H3
  • Key:MKTRMPIBOZYXTR-UHFFFAOYSA-N

AZD3676 is a drug which acts as a potent and selective antagonist for the 5-HT1A receptor and 5-HT1B receptors, with some selectivity for 5-HT1A. It has been researched for potential applications in the treatment of cognitive impairment in Alzheimer's disease.12

See also

See also

References

References

  1. US patent 8859534, Malmstrom JS, Andersson JS, Nordvall GS, Gyback HS, Terp GS, Weigelt TS, Linde CE, Johansson AS, "2-carboxamide-7-piperazinyl-benzofuran derivatives", published 2013-02-04, issued 2014-10-14, assigned to Acturum Life Science AB [Se] and Astrazeneca AB [Se] 
  2. Varnäs K, Juréus A, Johnström P, Ahlgren C, Schött P, Schou M, et al. (September 2016). "Integrated Strategy for Use of Positron Emission Tomography in Nonhuman Primates to Confirm Multitarget Occupancy of Novel Psychotropic Drugs: An Example with AZD3676". The Journal of Pharmacology and Experimental Therapeutics. 358 (3): 464–471. doi:10.1124/jpet.116.234146. PMID 27402278.